Etiprednol dicloacetate (BNP-166; ethyl-17alpha-dichloroacetoxy-11beta-hydroxyandrosta-1,4-diene-3-one-17beta-carboxylate) is a new soft steroid. The compound proved to be a dissociated glucocorticoid, showing a reduction in transactivating activity while preserving transrepressive abilities. The compound effectively decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture. The significant local effect of the compound will very likely be accompanied by a drastically reduced systemic activity indicating an encouraging selectivity of the pharmacological action of etiprednol dicloacetate. Etiprednol dicloacetate had been in a clinical trial for the treatment of allergic rhinitis, asthma and Crohn's disease. However, development has been discontinued.

Meclorisone is a synthetic corticosteroid exerting anti-inflammatory activity.

Prednival is prednisolone derivative patented by Francesco Vismara, Societa per Azioni as anti-inflammatory and progestational agent.

Fenestrel (ORF-3858) is a nonsteroidal antizygotic compound. It antagonizes progesterone. Fenestrel is a post-coital contraceptive.

Ethynerone (MK 665) is an oral contraceptive steroid. In preclinical studies, it induced mammary tumors.

Procinonide is a derivative of fluocinolone acetonide that has been applied topically with fluocinonide and ciprocinonide in the management of various skin disorders.

Thyromedan is a thyroalkanoic acid derivative with hypocholesterolemic activity. In clinical trials, Thyromedan in daily doses of 8 to 32 mg caused a decrease in serum cholesterol levels. The serum total triglycerides and the α- and β-lipoprotein partition of cholesterol and triglycerides were unaffected.

Thyroxine I-131 is a radiolabeled thyroid hormone that has been studied as a diagnostic agent for thyroid cancer. In pharmacokinetic studies, Thyroxine I-131 shows broad tissue distribution and 99% of the ingested radiolabeled Thyroxine may be found in the skin, intestines, muscles, blood, bones, liver, and thyroid glands of rats.

Fluocinolone participated in clinical trials for the treatment of Oral Lichen Planus and Candida Infection.